12th International Conference of Pharmaceutical Sciences

CARAS is an airway disease that encompasses the clinical manifestations of allergic rhinitis and asthma with the same physiopathology. MHTP is a synthetic tetrahydroisoquinoline alkaloid with anti-inflammatory activity in acute and pulmonary allergic inflammatory models. BALB / c mice were submitted to CARAS protocol and treated, orally or intranasal, with MHTP (5 mg/kg). The molecule inhibited the eosinophil migration to the nasal and pulmonary cavities and tissues through inhibition of p38 and ERK1 / 2 MAP Kinase pathways. Besides, MHTP decreased the production of TSLP, IL-5, and TGF-β as well as IgE-allergen specific, pulmonary tissue remodeling, bronchial hyperactivity and clinical signs of rhinitis. These data demonstrated that MHTP presented an anti-inflammatory effect on the CARAS model via the eosinophil MAP Kinase inhibitory pathway. This alkaloid is a strong candidate for clinical trials and inclusion of it in the pharmacotherapeutic arsenal of allergies.